We’re living in interesting times and I mean that in the Chinese curse kind of way. We can’t seem to stop to catch our breath… Read More »MYND Life Sciences (MYND.C) provides unorthodox route to better mental health
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news.… Read More »Psyched for this weeks news from CYBN.NE, PSYC.C, MNMD.Q, MSET.C, FTRP.Q, MYCO.NE, RVV.C, FH.NE, CMND.C, ATAI.Q
MindMed (MMED.NE, MNMD.Q) announced the start of a Phase 1 trial to assess the safety, pharmacokinetics and pharmacodynamics of DMT. DMT, properly known as N,N-Dimethyltryptamine… Read More »MindMed (MND.Q) announces intravenous DMT Phase 1 study
Mind Medicine (MMED.NE, MNMD.Q) announced that J.R. Rahn is stepping down from his roles as CEO and director. Rahn was a co-founder of the company… Read More »MindMed (MNMD.Q) CEO J.R. Rahn steps down
Mind Medicine (MMED.NE) announced the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from a pooled secondary analysis… Read More »MindMed (MMED.NE) publishes LSD dosing trial for personalized dosing
The notion of magic mushroom market offering after the legalization of cannabis has been floated time and again since long before cannabis legalization was even… Read More »The mushroom market roundup – who to look out for in 2021 featuring TRIP.C, MMED.E, XPHY.C, NUMI.V, and PULL.C
Shroom BOOM! MindMed has been one of the talk on the street, with price jumping over 50% this month and market cap exceeding 1 Billion!… Read More »Shroom Boom: MindMed (MMED), Numinus (NUMI), Red Light Holland (TRIP) and Mydecine (MYCO)
Mind Medicine (MMED.E) closed a bought deal short-form prospectus offering, issuing 27,381,500 units for $1.05 and brought in $28,750,575 today, according to a press release.… Read More »Mind Medicine (MMED.E) closes a private placement and keeps going on their psychedelic research
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ NEW YORK, Oct.… Read More »MindMed Announces $25 Million Bought Deal Public Offering
Mind Medicine (MMED.E) is raising money to found and launch a clinical training program focused on developing psychedelic-assisted therapies and medicines at New York University’s… Read More »Mind Medicine (MMED.E) and NYU Langone Health are raising money for psychedelics clinical trial
